Similar articles

• Use of OKT3 in kidney, pancreas, and liver transplantation.

  D'Alessandro AM, Pirsch JD, Melzer JS, Sollinger HW, Kalayoglu M, Reed A, Knechtle SJ, Belzer FO. D'Alessandro AM, et al. Transplant Proc. 1990 Aug;22(4):1748-9. Transplant Proc. 1990. PMID: 2117796 No abstract available.
• Single center randomized trial using ATG v OKT3 treatment in steroid resistant rejection crises after kidney transplantation.

  Blümke M, Kirste G, Wanner U, Wilms H. Blümke M, et al. Transplant Proc. 1989 Feb;21(1 Pt 2):1747. Transplant Proc. 1989. PMID: 2652571 Clinical Trial. No abstract available.
• Quadruple-drug induction therapy in combined renal and pancreatic transplantation--OKT3 versus ATG.

  Illner WD, Theodorakis J, Abendroth D, Schleibner S, Stangl M, Landgraf R, Land W. Illner WD, et al. Transplant Proc. 1990 Aug;22(4):1586-7. Transplant Proc. 1990. PMID: 2117795 Clinical Trial. No abstract available.
• Nursing implications of immunosuppression in transplantation.

  Shaefer M, Williams L. Shaefer M, et al. Nurs Clin North Am. 1991 Jun;26(2):291-314. Nurs Clin North Am. 1991. PMID: 1904575 Review.
• Acute renal allograft rejection: the role of monoclonal antibodies in treatment: experience with orthoclonal anti-T3 cell antibody.

  McLigeyo SO, Notghi A, Anderton JL, Dick J. McLigeyo SO, et al. East Afr Med J. 1990 Sep;67(9):667-73. East Afr Med J. 1990. PMID: 2123786 Review.